Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model.
Intravenous zanamivir is recommended for the treatment of hospitalized patients with complicated oseltamivir-resistant influenza virus infections. In a companion paper, we show that the time above the 50% effective concentration (time>EC(50)) is the pharmacodynamic (PD) index predicting the inhibition of viral replication by intravenous zanamivir. However, for other neuraminidase inhibitors, the ratio of the area under the concentration-time curve to the EC(50) (AUC/EC(50)) is the most predictive index. Our objectives are (i) to explain the dynamically linked variable of intravenous zanamivir by using different half-lives and (ii) to develop a new, mechanism-based population pharmacokinetic (PK)/PD model for the time course of viral load. We conducted dose fractionation studies in the hollow-fiber infection model (HFIM) system with zanamivir against an oseltamivir-resistant influenza virus. A clinical 2.5-h half-life and an artificially prolonged 8-h half-life were simulated for zanamivir. The values for the AUC from 0 to 24 h (AUC(0-24)) of zanamivir were equivalent for the two half-lives. Viral loads and zanamivir pharmacokinetics were comodeled using data from the present study and a previous dose range experiment via population PK/PD modeling in S-ADAPT. Dosing every 8 h (Q8h) suppressed the viral load better than dosing Q12h or Q24h at the 2.5-h half-life, whereas all regimens suppressed viral growth similarly at the 8-h half-life. The model provided unbiased and precise individual (Bayesian) (r(2), >0.96) and population (pre-Bayesian) (r(2), >0.87) fits for log(10) viral load. Zanamivir inhibited viral release (50% inhibitory concentration [IC(50)], 0.0168 mg/liter; maximum extent of inhibition, 0.990). We identified AUC/EC(50) as the pharmacodynamic index for zanamivir at the 8-h half-life, whereas time>EC(50) best predicted viral suppression at the 2.5-h half-life, since the trough concentrations approached the IC(50) for the 2.5-h but not for the 8-h half-life. The model explained data at both half-lives and holds promise for optimizing clinical zanamivir dosage regimens.
Virology Therapeutics and Pharmacodynamics Laboratory, Center for Biodefense and Emerging Infections, Ordway Research Institute, Center for Medical Sciences, 150 New Scotland Avenue, Albany, New York 12208, USA.
Ashley N
AN
Brown
Jürgen B
JB
Bulitta
James J
JJ
McSharry
Qingmei
Q
Weng
Jonathan R
JR
Adams
Robert
R
Kulawy
George L
GL
Drusano
D000818:Animals; D019540:Area Under Curve; D002460:Cell Line; D004285:Dogs; D008962:Models, Theoretical; D009975:Orthomyxoviridae / Q000187:drug effects*; D053243:Zanamivir / Q000494:pharmacology*
D053243:Zanamivir
Antimicrob Agents Chemother. 2009 Oct;53(10):4115-26
19620324
MMWR Morb Mortal Wkly Rep. 2009 Aug 21;58(32):893-6
19696719
MMWR Morb Mortal Wkly Rep. 2009 May 1;58(16):433-5
19407738
Expert Opin Pharmacother. 2001 Oct;2(10):1671-83
11825310
Antimicrob Agents Chemother. 1980 May;17(5):865-70
7396473
MMWR Morb Mortal Wkly Rep. 2009 Sep 11;58(35):969-72
19745803
Antimicrob Agents Chemother. 2009 May;53(5):2120-8
19273672
N Engl J Med. 2009 Nov 12;361(20):1935-44
19815859
Clin Pharmacokinet. 1999;36 Suppl 1:1-11
10429835
N Engl J Med. 2005 Dec 22;353(25):2633-6
16371626
J Virol. 2006 Aug;80(15):7590-9
16840338
Antimicrob Agents Chemother. 2010 Aug;54(8):3442-50
20498316
PLoS One. 2010 Feb 22;5(2):e9332
20179772
N Engl J Med. 2009 Jun 18;360(25):2605-15
19423869
Clin Pharmacokinet. 1999;36 Suppl 1:13-9
10429836
Antimicrob Agents Chemother. 2011 Apr;55(4):1740-6
21263046
Pharm Res. 2006 Sep;23(9):2036-49
16906454
Nature. 2009 Aug 20;460(7258):1021-5
19672242
MMWR Morb Mortal Wkly Rep. 2010 Jan 8;58(51):1436-40
20057350
J Pharmacokinet Pharmacodyn. 2001 Oct;28(5):481-504
11768292
J Clin Microbiol. 2010 Nov;48(11):4228-34
20861338
Science. 2009 Jul 10;325(5937):197-201
19465683
Antiviral Res. 2002 Jan;53(1):47-61
11684315
Antimicrob Agents Chemother. 2001 Jul;45(7):2115-8
11408232
Expert Opin Investig Drugs. 2002 Jun;11(6):859-69
12036429
Antimicrob Agents Chemother. 2009 Jun;53(6):2375-81
19364864
J Theor Biol. 2008 Sep 21;254(2):439-51
18653201